Lido Advisors LLC Acquires 10,125 Shares of DexCom, Inc. $DXCM

Lido Advisors LLC boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 43.6% in the 1st quarter, HoldingsChannel reports. The fund owned 33,324 shares of the medical device company’s stock after buying an additional 10,125 shares during the quarter. Lido Advisors LLC’s holdings in DexCom were worth $2,093,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. Reflection Asset Management bought a new stake in shares of DexCom in the 4th quarter worth approximately $25,000. Ascentis Independent Advisors purchased a new stake in shares of DexCom in the 1st quarter worth about $25,000. MCF Advisors LLC purchased a new stake in DexCom in the fourth quarter worth about $32,000. ORG Partners LLC grew its stake in shares of DexCom by 124.3% in the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after buying an additional 281 shares during the last quarter. Finally, DV Equities LLC bought a new position in shares of DexCom during the fourth quarter valued at $36,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $71.54 on Monday. The business has a 50 day simple moving average of $72.46 and a two-hundred day simple moving average of $68.95. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The firm has a market capitalization of $27.61 billion, a PE ratio of 30.57, a price-to-earnings-growth ratio of 1.18 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the prior year, the firm earned $0.32 EPS. The company’s revenue for the quarter was up 15.0% compared to the same quarter last year. On average, equities analysts predict that DexCom, Inc. will post 2.57 EPS for the current year.

Analysts Set New Price Targets

DXCM has been the subject of several analyst reports. Bank of America reduced their price target on shares of DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Raymond James Financial reiterated a “strong-buy” rating and issued a $91.00 price objective on shares of DexCom in a research note on Monday, June 8th. Citigroup reiterated a “buy” rating and set a $84.00 target price (up from $79.00) on shares of DexCom in a research report on Thursday, May 28th. Barclays reaffirmed an “underweight” rating and set a $64.00 price target (down from $67.00) on shares of DexCom in a report on Monday, May 18th. Finally, Robert W. Baird set a $80.00 price objective on DexCom in a research report on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average price target of $85.36.

Insider Buying and Selling

In other DexCom news, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the completion of the sale, the director directly owned 25,007 shares in the company, valued at $1,500,670.07. This trade represents a 3.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the sale, the executive vice president directly owned 106,353 shares of the company’s stock, valued at $8,034,969.15. The trade was a 1.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 71,750 shares of company stock valued at $5,163,241 over the last three months. Corporate insiders own 0.28% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.